17:24 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
21:24 , Aug 16, 2018 |  BC Extra  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
16:19 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support...
21:41 , Jul 18, 2018 |  BC Extra  |  Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support...
16:27 , May 4, 2018 |  BC Week In Review  |  Clinical News

Regeneron halting higher doses in fasinumab trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab. Regeneron will modify ongoing trials to continue with two lower doses, President and CSO George...
17:19 , May 3, 2018 |  BC Extra  |  Company News

Regeneron halting higher doses in fasinumab trials

In its 1Q18 earnings, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab (REGN475). Regeneron will modify ongoing trials to continue with two lower...
16:34 , Jan 12, 2018 |  BC Week In Review  |  Company News

Pfizer ending discovery and early neuroscience programs

Pfizer Inc. (NYSE:PFE) said it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates the move will result in 300 layoffs "over the coming...
01:03 , Jan 6, 2018 |  BC Extra  |  Company News

Pfizer ending discovery, early neuroscience program

Pfizer Inc. (NYSE:PFE) said Friday it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates the move will result in 300 layoffs "over the...
20:27 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial to evaluate single ascending doses of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of...
22:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of the knee. LEVI-04 is a...